Kalia (for Paul Choi)'s questions to Kiniksa Pharmaceuticals International PLC (KNSA) leadership • Q1 2025
Question
Kalia, on behalf of Paul Choi from Goldman Sachs, asked to what extent the Medicare Part D changes drove the increase in new prescribers and if this positive impact is expected to persist.
Answer
Chief Commercial Officer Ross Moat clarified that the Medicare Part D impact was not from new prescribers, but rather a one-time bolus of existing patients on free goods who converted to paid commercial therapy due to improved affordability. He characterized this as a one-time event and noted uncertainty around the dynamics of this patient group for the rest of the year.